Cargando…
Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial
BACKGROUND: Since lifestyle changes are main therapies for non-alcoholic fatty liver disease (NAFLD), changing dietary components (nutritional or bioactive) may play a parallel important role. Few studies have assessed the effects of curcumin on NAFLD (mainly antioxidant and anti-inflammatory effect...
Autores principales: | Jazayeri-Tehrani, Seyed Ali, Rezayat, Seyed Mahdi, Mansouri, Siavash, Qorbani, Mostafa, Alavian, Seyed Moayed, Daneshi-Maskooni, Milad, Hosseinzadeh-Attar, Mohammad-Javad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348610/ https://www.ncbi.nlm.nih.gov/pubmed/30705687 http://dx.doi.org/10.1186/s12986-019-0331-1 |
Ejemplares similares
-
Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): a trial protocol
por: Jazayeri-Tehrani, Seyed Ali, et al.
Publicado: (2017) -
Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial
por: Daneshi-Maskooni, Milad, et al.
Publicado: (2018) -
Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial
por: Daneshi-Maskooni, Milad, et al.
Publicado: (2019) -
The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial
por: Daneshi-Maskooni, Milad, et al.
Publicado: (2017) -
Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial
por: Naeini, Fatemeh, et al.
Publicado: (2021)